Prognostic factors related with survival in patients with pancreatic adenocarcinoma
about
LncRNAs in pancreatic cancerNAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerImpact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive JaundicesCorrelation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer.Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib.Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaNimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients.Lymph node 8a as a prognostic marker for poorer prognosis in pancreatic and periampullary carcinoma.Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer.Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
P2860
Q26739965-6A5AD4A2-4CBF-4DCE-9152-3BE9F8029C70Q33435134-454612A3-2722-4A9B-A54B-4AADA3EA16F1Q34539541-D90D0B7E-5F7C-4931-AA09-E1E556A51DCEQ36194616-541C6FB8-35BE-4F10-A918-3DBF290D2908Q36467279-15F68212-2BF5-4529-B64F-36E7DBD923CCQ37089422-B12AF2EB-0A70-48A1-BAEF-50503CC10113Q37525286-E6266BF4-FE48-4709-B45B-A96C09321C24Q38378638-D24D4141-05E2-4885-A26A-C7B6A24E411AQ38799932-87BC5D75-AFB0-49D3-B2AC-279EC3E14F76Q47101670-55D3639E-356B-4AAC-A6D7-76B0D008DDADQ47771429-7A5B35C4-21B1-4B37-90D9-C303A141BA6FQ49359449-97C0A53D-3F08-43A5-AA0F-5C9A817EF25CQ55492890-2DFBE90A-F9FD-405B-8B1E-DC6FCD0E4783Q58744824-B44DBCC5-10D4-4BAA-9E07-C61A3148DF86
P2860
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
@en
type
label
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
@en
prefLabel
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
@en
P2860
P1476
Prognostic factors related with survival in patients with pancreatic adenocarcinoma
@en
P2093
Ahmet Bilici
P2860
P304
10802-10812
P356
10.3748/WJG.V20.I31.10802
P407
P577
2014-08-01T00:00:00Z